Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2018-000397
Abstract: Introduction Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used… read more here.
Keywords: data six; safety; survival data; clinical trials ... See more keywords